Home / Health / India gets third Covid-19 vaccine as SEC clears Russia's Sputnik V

India gets third Covid-19 vaccine as SEC clears Russia's Sputnik V

Final nod from DCGI soon, jab likely at $3/dose

Sputnik V, Dr Reddy’s Laboratories, DRL, coronavirus, vaccine, covid-19

Premium

Sputnik V has claimed an efficacy of 91.6 per cent in the interim analysis of the phase 3 clinical trial, which included data on 19,866 volunteers in Russia

Sohini Das Ram Prasad Sahu Mumbai

3 min read Last Updated : Apr 13 2021 | 1:12 AM IST

Amid vaccine shortage forcing many inoculation centres to shut down, Russia’s Sputnik V has got the nod of the Subject Expert Committee (SEC) for emergency use. An approval from the Drugs Controller General of India (DCGI) was awaited at the time of going to press. Sputnik V will be the third Covid-19 vaccine in India, besides Covishield and Covaxin.

Dr Reddy’s Laboratories (DRL) had in September 2020 entered a partnership with the Russian Direct Investment Fund (RDIF) for clinical trials and distribution rights of Sputnik V in India. It completed the bridging trials in the country in February.

For the Indian

Topics : Coronavirus Coronavirus Vaccine Russia Dr Reddy's Laboratories Vaccine Vaccination

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in